Seawolf raises 100 million dollars for DNA medicines that can be given repeatedly and signs a Sanofi deal worth up to 1,2 billion dollars
Seawolf raises 100 million dollars for DNA medicines that can be given repeatedly and signs a Sanofi deal worth up to 1,2 billion dollars
On November 16, Seawolf emerged from stealth with 100 million dollars from Versant Ventures, Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics, and other investors. Seawolf signed an agreement with Sanofi to develop medicines for bleeding disorders and other undisclosed diseases, with up to 1,2 billion dollars in development and sales milestone payments plus royalties. Its TRIDENT platform packages DNA encoding a therapeutic protein in lipid (fat) nanoparticles, like those used in mRNA vaccines.
To make liver cells produce a protein themselves, its gene is delivered to them, usually by an adeno-associated virus, AAV, modified to be harmless. The virus carries the DNA into the nucleus, where it is read. After treatment, the body produces antibodies against the virus. In a trial of the AAV gene therapy Roctavian for hemophilia A, modeling of two-year data estimated that production of factor VIII, a blood-clotting protein, falls by half approximately every 123 weeks. A review in Annual Review of Medicine states that the current state of clinical development “likely allows only one systemic administration of an AAV vector in a lifetime.”
Lipid nanoparticles offer an alternative: they release their cargo into the cytoplasm, where mRNA is read. According to Seawolf, mRNA therapies produce protein for a short time, while DNA in the nucleus supports longer production. DNA must first reach the nucleus, however. The nuclear envelope breaks down during cell division, but liver cells divide slowly, so only a small fraction of the DNA reaches the nucleus. Inflammation is a second barrier. In experiments by Jacob Brenner at the University of Pennsylvania, plasmid DNA in conventional nanoparticles caused acute inflammation: at typical therapeutic doses, all mice of one strain died, while mRNA in the same nanoparticles was tolerated. Seawolf describes its DNA as “immunologically quiet,” saying it triggers a weaker immune response than plasmids. DNA requires a specially designed nanoparticle, CEO Elizabeth Alcamo notes; Seawolf selected its formulation by testing variants in primates.
To get DNA into the nucleus, TRIDENT uses a “helper factor,” a protein that the cell produces from mRNA delivered in the same nanoparticle as the DNA. Seawolf's patent application describes a system with the same components: the DNA contains an “address” made up of several repeats of a short sequence, and the mRNA encodes a protein that recognizes this address and binds to the DNA. The protein carries a signal that cells use to admit their own proteins into the nucleus. The applicants propose that it carries the DNA into the nucleus with it. Compared with the same DNA delivered without mRNA, protein production increased 10–40-fold in cultured nondividing human liver cells at the highest mRNA dose. In mice, human factor IX levels increased 2–5-fold; a deficiency of this protein causes hemophilia B. The increase disappeared when either the address on the DNA or the signal on the protein was absent.
Unlike AAV, the medicine can be given repeatedly until each patient reaches “the level of protein production or gene correction they need,” Alcamo writes. The lead program, for metabolic diseases, aims to allow patients who receive regular protein treatments to be treated once every six months or once a year. According to Reuters, the program targets muscle growth and fat reduction. The company says that, in primates, protein production remained above therapeutic levels at safe doses.
Seawolf expects to select a drug candidate by the end of 2027 and apply to begin human trials by the end of 2028. To do that, Alcamo tells Reuters, “we will probably need to raise additional capital.”
- https://seawolftx.com/seawolf-therapeutics-debuts-with-100-million-to-advance-dna-based-therapeutics/
- https://doi.org/10.1056/nejmoa2211075
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9892335/
- https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(25)00377-6
- https://patents.google.com/patent/US20260234655A1/en
- https://www.fiercebiotech.com/biotech/dna-delivery-biotech-seawolf-surfaces-alongside-investors-novartis-lilly-and-partner-sanofi
- https://live.euronext.com/en/financial-news/dna-drug-developer-seawolf-launches-100-million-funding-sanofi-deal